
We’ve closed our $5 Billion funding round co-led by Greenoaks and Sequoia Capital to build the future of medicine and bioengineering with AI. isomorphiclabs.com/articles/…
✓Solve all disease. Developing and applying frontier AI to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.

We’ve closed our $5 Billion funding round co-led by Greenoaks and Sequoia Capital to build the future of medicine and bioengineering with AI. isomorphiclabs.com/articles/…

Catch our workshops: Agentic AI for Biological Discovery: AgenticLS Sydney | Dec 11 | Eli M Carrami agenticls.github.io/schedule… ML4Molecules: Agentic Systems for Molecular Sciences Paris | Dec 13 | Michael Schaarschmidt moleculediscovery.github.io/…

Want to learn how our AI team is working towards a new future for how medicines are designed and made? Don’t miss IsoLabs at #NeurIPS2026. We’ll be in Sydney, Paris, and Atlanta, unpacking our core technical philosophy and sharing how we leverage SOTA agentic models, our conviction in building simulation and world models, and our plan to unlock the bottlenecks holding AI for biology back today. If you’re working on AI and want to see its impact in life sciences, let’s talk. bit.ly/4Ae6tvR

Nobel laureate Sir Paul Nurse literally mapped out the control of cell division. He recently spent time with us, doing what he does best: asking the hard questions that push our science further and challenge our team to keep thinking bigger.

Frameworkless ML Serving (Thu 1:50 PM) events.linuxfoundation.org/k…

Anatomy of a Scheduler Outage (Wed 11:00 AM) events.linuxfoundation.org/k…

Operating ML at scale is a constant battle of trade-offs: 1. Scaling thousands of models without the rigidity and complexity of ML frameworks 2. Preventing your scheduler from stalling under massive, bursty workloads We're covering both at #KubeCon NA.

Today, Isomorphic Labs joins the Virtual Biology Initiative (VBI) as a founding member. We are helping build an open resource for the global research community to accelerate how we understand and treat disease. Read more here: isomorphiclabs.com/articles/…

Previously, 85% of proteins associated with human disease were deemed intractable – their shapes and function made them less suitable for traditional chemical screening in the lab. Moving from experimental screening to AI generative design on a computer, we have seen these targets drastically open up the potential to design molecules with atomic precision, fundamentally expanding the number of diseases we can treat.

Over the last 50 years, computer-aided design has revolutionised almost every major engineering field – but its revolution in making medicines has only just begun. Moving from manual execution to AI-driven design unlocks a depth and scale that was previously impossible. Our drug design engine, IsoDDE, intelligently searches vast chemical spaces to design functional molecules ready for the real world. What used to take months of lab work now happens computationally in just days. The visualisation below is a representation of our drug design agent working autonomously over a 2-4 day period. Starting with a strict design specification (the biological target and desired molecular properties), our AI agent autonomously searches and iteratively generates new molecule designs that result in real world functional progress.

Hear from AI expert and Isomorphic Labs President @maxjaderberg in his new blog, where he lays out what’s driving today’s breakthroughs in AI drug design and what the road ahead looks like. isomorphiclabs.com/articles/…

Empirical Methods → Exquisitely Engineered Molecules How we make new medicines has evolved for centuries, but modern AI represents the biggest leap yet: moving from resource-intensive iterative design-make-test cycles to engineered precision.

From small molecules to complex biologics, the universe of potential medicines spanning multiple modalities is astronomically vast. To put it in perspective: conservative estimates place the vast chemical search space for small, drug-like molecules near 10^60. The observable universe contains fewer stars – somewhere between 10^22 and 10^24. The answers to drug discovery’s toughest challenges exist within this vast space. And now, our drug design engine (IsoDDE) gives us the capability to navigate it.

Drug discovery is incredibly complex, but you don't need a background in biology to help solve it. Hear from software engineer, Bartosz Bacewisz, on how transferable skills in tech and a shared motivation are helping us build frontier AI models to reimagine medicine. bit.ly/424SMjZ

Full podcast episode with @FryRsquared here: bit.ly/4hRR8Lw

The prediction: 5 years for the industry to realise AI is essential in drug design and development – @maxjaderberg. While this episode aired a year ago, we’ve been building for almost 5 years already, and have always held the conviction that our AI will redefine how new medicines are made.